Vosoritide · source year

Vosoritide research records in 2024

9 selected, source-linked Vosoritide records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.

Dated records

9 selected records.

Evidence types

3 represented types.

Cited sources

9 distinct public records.

Explore 2024 by evidence type

3 types

Cited chronology

Vosoritide records dated 2024

Open in the filterable feed →

December 2024

1 record

November 2024

1 record

October 2024

1 record

Literature metadata

Vosoritide therapy in children with achondroplasia under 5 years of age.

PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

July 2024

1 record

June 2024

1 record

May 2024

1 record

Literature metadata

Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.

PubMed lists PMID 38813446 in EClinicalMedicine as Journal Article, with publication-date metadata of 2024-04-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

April 2024

2 records

March 2024

1 record

Regulatory

Federal Register notice 2024-04479

The Federal Register published notice 2024-04479, attributed to FDA and its parent HHS department, on 2024-03-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO,” and PeptideScanner's exact reviewed identity mapping connects the document to Vosoritide.

Source: Federal Register via GovInfo ↗